Data on cholesterol drug fenofibrate lead to FDA advisory

11/9/2011 | Medscape (free registration)

Data from the ACCORD Lipid trial showed the cholesterol-lowering drug fenofibric acid or fenofibrate may not reduce the risk of major cardiovascular events, leading the FDA to issue a safety communication and update prescribing information. The agency also asked for a trial to study the medication's cardiovascular effects in patients on statins.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC